This is the authors' abstract. We don't add key points for this paper.
Object: Optimization of treatment in early stages of combined fundus pathology diabetic retinopathy (DR without DME) and dry type of age-related macular degeneration (AMD AREDS I, II, III). Patients and methods:120 people (150 eyes). Study group 1 (SG1) — control 60 people. (60 eyes); study group 2 (SG2) — 30 people. (30 eyes) — DRI without DME and AMD AREDS I, II, III) treatment: 1 year with angioprotective calcium dobezilate (Doxi- Hem®) dose of 500 mg 3 after 6 months, 500 mg once a day for 6 months and at the same time 1 year antioxidant agent (Retinorm) 1 capsule 3 times a day; study group 3 group (SG3) 30 people. (30 eyes) — with DRO and dry type of AMD (AREDS I, II, III) 1 year Retinorm 1 capsule 3 times a day; study group 4 (SG4) with DRI without DME — 30 people. (30 eyes) 1 year Doxi-Hem®. Monitoring: monthly standard ophthalmologic examination, control of diabetes mellitus (HbA1C) compensation, VEGF-A vascular endothelial growth factor in tear. Results.Visual acuity increased on the background of treatment in all three groups (IG2,3,4): in SG2 from 0.72 ± 0.02 to 0.87 ± 0.02, p < 0.05; the thickness of the retina decreased from 290.2 ± 2.1 to 268.85 ± 2.2 μm, p < 0.05, the photosensitivity increased from 21.0 ± 0.2 to 25.1 ± 0.2 dB p < 0.05; in the tear VEGF-A to 415.4 ± 4.6 pg/ml, p < 0.05. In SG3, visual acuity increased from 0.74 ± 0.02 to 0.88 ± 0.02, p < 0.05; the thickness of the retina decreased from 287.7 ± 2.0 to 272.8 ± 2.2 μm (р < 0.05); increased photosensitivity from 21.3 ± 0.2 to 24.5 ± 0.2 dB, p < 0.05; in the VEGF-A slip to 416.6 ± 5.0 pg/ml, p > 0.05. In IG4 visual acuity increased from 0.70 ± 0.02 to 0.78 ± 0.02, p < 0.05; the thickness of the retina decreased from 288.1 ± 4.4 to 280.1 ± 2.4 μm, р < 0.05; the photosensitivity increased from 21.2 ± 0.2 to 23.2 ± 0.2 dB; VEGF-A up to 415.9 ± 3.8 pg/ml, p > 0.05. Conclusion. Combined therapy of angioprotective (Doxi-Hem®) and antioxidant therapy (Retinorm) with timely appointment at early dry stages of combined pathology (DR and AMD) will allow to stabilize, delay the development of severe forms of the disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
I. V. Vorobyeva (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: